National Health (Originator Brand) Amendment Determination 2019 (No. 5) (PB 64 of 2019) (Cth)

PB 64 of 2019

National Health (Originator Brand) Amendment Determination 2019 (No. 5)

National Health Act 1953

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated        26  July 2019

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Originator Brand) Amendment Determination 2019 (No. 5).

(2)     This Determination may also be cited as PB 64 of 2019.

1. Commencement

This Determination commences on 1 August 2019.

1. Amendments to PB 100 of 2015

Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]                   Schedule 1 (after table item 106)

insert:

106A	Hydromorphone	Dilaudid Dilaudid-HP	Injection
		Dilaudid Jurnista	Oral

[2]                   Schedule 1 (after table item 224B)

insert:

224C Tenofovir with emtricitabine and efavirenz Atripla

[3]                   Schedule 1 (after table item 233A)

insert:

233B Trastuzumab Herceptin
Herceptin SC